After Atara Biotherapeutics announced an expanded partnership with Pierre Fabre Laboratories for the U.S. and remaining global commercial markets for tab-cel for up to $640M and tiered royalties on net sales, Mizuho analyst Salim Syed said the firm values the agreement at a risk-adjusted $450M, or $4-plus per share. The firm, which noted that Atara also announced a staff reduction of 30% and estimates this equates to an additional $10M or so of annual opex savings, keeps a Buy rating and $31 price target on Atara shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATRA:
- Atara Biotherapeutics announces restructuring and 30% workforce reduction
- Atara expands global tab-cel partnership up to $640M with Pierre Fabre
- Atara Biotherapeutics reports Q3 EPS (66c), consensus (66c)
- Citi opens ‘negative Catalyst Watch’ on Atara into MS data
- Poseida Therapeutics names Kristin Yarema, Ph.D as CEO, effective Jan 1, 2024